Amy Major
Impact in
- Infectious Diseases top 5%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
-
- Antibiotics Pharmacokinetics and Efficacy
Papers in
-
- COVID-19 Clinical Research Studies 2
- Genetics 2
- Genetic Associations and Epidemiology 2
In The Last Decade
Amy Major
6 papers receiving 574 citations
Amy Major's Hit Papers
Peers
Comparison fields: 5 of 57
- Infectious Diseases 285
- Pharmacology 58
- Applied Microbiology and Biotechnology 9
- Genetics 93
- Epidemiology 63
Countries citing papers authored by Amy Major
This map shows the geographic impact of Amy Major's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amy Major with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amy Major more than expected).
Fields of papers citing papers by Amy Major
This network shows the impact of papers produced by Amy Major. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amy Major. The network helps show where Amy Major may publish in the future.
No co-authors to show.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis Hit paper breakdown → | 2022 | 231 |
| 2 | GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19 Hit paper breakdown → | 2023 | 125 |
| 3 | Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis Hit paper breakdown → | 2024 | 94 |
| 4 | Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2023 | 84 |
| 5 | 2023 | 60 | |
| 6 | 2026 | 3 |
About Amy Major
Amy Major is a scholar working on Infectious Diseases, Genetics, Pharmacology, Pulmonary and Respiratory Medicine and Nuclear Energy and Engineering, having authored 6 papers that have together received 597 indexed citations. Recurring topics across this work include COVID-19 Clinical Research Studies (2 papers), Genetic Associations and Epidemiology (2 papers), Antibiotics Pharmacokinetics and Efficacy (1 paper) and Respiratory Support and Mechanisms (1 paper). The work is most often cited by research in Infectious Diseases (285 citations), Pharmacology (58 citations), Applied Microbiology and Biotechnology (9 citations), Genetics (93 citations) and Epidemiology (63 citations). Their work appears in journals such as The Lancet, Nature, The Lancet Respiratory Medicine and JAMA.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.